Real‑world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib
Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years.
Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years.
This statement confirms the demographic and disease profile of the real‑world cohort receiving fedratinib, illustrating that the drug is being used in typical patients with primary myelofibrosis at a standard dose and age range.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Management of Acute Myeloid Leukemia: A Review
- Old cells, new tricks—important clue to AML diagnosis and cure discovered
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML